Decentralized Trials – It Takes Community Based Approach, Are we Really Making Progress?

Douglas Landsittel Chair
Indiana University
 
Ryan Gryder Panelist
Takeda Pharmaceuticals
 
Margaret Gamalo Panelist
Pfizer
 
Theodore Lystig Panelist
 
Jonathan Helfgott Panelist
Johns Hopkins University
 
Vipin Arora Organizer
Eli Lilly and Company
 
Tuesday, Aug 8: 8:30 AM - 10:20 AM
1303 
Invited Panel Session 
Metro Toronto Convention Centre 
Room: CC-206C 
Decentralized trials have huge potential to bridge the gap between the data needed by patients who are potential users of a treatment than the data generated by those who participated in studies conducted by sponsors and evaluated by the regulators. This panel will go over the challenges and vast opportunities that exist to expand the experience during clinical studies by outreaching much larger pool of patient population, using digital technology and other means including fully virtual studies. The similarity of DCTs with Pragmatic clinical trials will also be covered by a panelist. The vision on DCTs by 2030 would also be shared.

Applied

Yes

Main Sponsor

Section for Statistical Programmers and Analysts

Co Sponsors

Health Policy Statistics Section
International Society for Clinical Biostatistics